Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2024-07-11

FDA Approved: OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE — Original Application (Ascend Laboratories, LLC)

View source ↗

Summary

FDA approved a generic fixed-dose combination of olmesartan medoxomil and hydrochlorothiazide for hypertension under ANDA 207037, manufactured by Ascend Laborat…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Olmesartan Medoxomil and Hydrochlorothiazide (olmesartan medoxomil; hydrochlorothiazide)

Snippet

ORIG AP for OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE (OLMESARTAN MEDOXOMIL AND HYDROCHLOROTHIAZIDE)